Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Abstract Background Thymidine kinase 1 (TK1) is a cell cycle-regulated enzyme with peak expression in the S phase during DNA synthesis, and it is an attractive biomarker of cell proliferation. Serum TK1 activity has demonstrated prognostic value in patients with early-stage breast cancer. Because cy...

Full description

Bibliographic Details
Main Authors: Nusayba Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W. Northfelt, Matthew P. Goetz, Andres Forero, Mattias Bergqvist, Jakob Karen, Magnus Neumüller, Edward M. Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew Ellis, Cynthia X. Ma
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Breast Cancer Research
Subjects:
Breast cancer
Thymidine kinase
Palbociclib
Anastrozole
Neoadjuvant
Biomarker
Online Access:http://link.springer.com/article/10.1186/s13058-017-0913-7

Internet

http://link.springer.com/article/10.1186/s13058-017-0913-7

Similar Items